Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601443 | 1.00 | HPGD (0.59) | HPGDGAASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL22601545 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2HTTALDH1A1TSHRLMNA | |
| SCHEMBL22601541 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2HTTALDH1A1TSHRLMNA | |
| SCHEMBL30009291 | 0.83 | HPGD (0.64) | HPGDGAASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL14868382 | 0.81 | SMN1; SMN2 (0.71) | HPGDSMN1; SMN2HTTALDH1A1TSHR | |
| SCHEMBL22601442 | 0.80 | GAA (0.59) | HPGDGAAHTTALDH1A1TSHR | |
| SCHEMBL17207185 | 0.80 | SMN1; SMN2 (0.69) | HPGDSMN1; SMN2HTTALDH1A1TSHR | |
| SCHEMBL22601453 | 0.80 | SMN1; SMN2 (0.69) | HPGDSMN1; SMN2HTTALDH1A1TSHR | |
| SCHEMBL21212469 | 0.79 | GAA (0.57) | HPGDGAAHTTALDH1A1LMNA | |
| SCHEMBL34462903 | 0.78 | GAA (0.56) | HPGDGAAHTTLMNACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | HPGD 2135/4885GAA 40/4885SMN1; SMN2 20/4885 |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | HPGD 1722/4885GAA 3024/4885SMN1; SMN2 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.